Skip to main content
Midas Edge

JANEL CORP

For the period ended Mar 31, 2024. Filed May 3, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 3, 2024

JANLStored price and day change unavailable

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 6. EXHIBIT INDEX

10.1First Amendment to Amended and Restated Credit Agreement, by and among Indco, Inc. a Tennessee corporation, Antibodies Incorporated, a California corporation, Aves Labs, Inc., an Oregon corporation, PhosphoSolutions LLC, a Nevada limited liability company, ImmunoChemistry Technologies LLC, a Minnesota limited liability company, ECM BioSciences, LLC, a Kentucky limited liability company, Stephen Hall, PHD LTD, an Indiana corporation, ImmunoBioScience Corp., a Washington corporation (collectively as borrowers) and Janel Corporation, a Nevada corporation, as guarantor, and First Merchants Bank, as bank. dated January 10, 2024
31.1Rule 13a-14(a)/15d-14(a) Certification of Principal Executive Officer (filed herewith)
31.2Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer (filed herewith)
32.1Section 1350 Certification of Principal Executive Officer (filed herewith)
32.2Section 1350 Certification of Chief Financial Officer (filed herewith)
101Interactive data files providing financial information from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 for the three and six months ended March 31, 2024 and 2023 in Inline XBRL (eXtensible Business Reporting Language) pursuant to Rule 405 of Regulation S-T: (i) Condensed Consolidated Balance Sheets as of March 31, 2024 and September 30, 2023, (ii) Condensed Consolidated Statements of Operations for the three and six months ended March 31, 2024 and 2023, (iii) Condensed Consolidated Statement of Changes in Stockholders’ Equity for the three and six months March 31, 2024 and 2023, (iv) Condensed Consolidated Statements of Cash Flows for the six months ended March 31, 2024 and 2023, and (v) Notes to Condensed Consolidated Financial Statements.
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in the Interactive Data Files submitted as Exhibit 101) (filed herewith)
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.